Skip to main content

Ataxin 7 Products

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with Spinocerebellar ataxia-7, contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The exact function of this gene is not known, however, since the encoded protein contains a nuclear localization sequence, and is found to be localized in the nucleus, it has been postulated to be a potential transcription factor. Alternative splicing, resulting in transcript variants encoding different isoforms, has been noted for this gene. (provided by RefSeq)
Show More

30 results for "Ataxin 7" in Products

30 results for "Ataxin 7" in Products

Ataxin 7 Products

The autosomal dominant cerebellar ataxias (ADCA) are a heterogeneous group of neurodegenerative disorders characterized by progressive degeneration of the cerebellum, brain stem and spinal cord. Clinically, ADCA has been divided into three groups: ADCA types I-III. ADCAI is genetically heterogeneous, with five genetic loci, designated spinocerebellar ataxia (SCA) 1, 2, 3, 4 and 6, being assigned to five different chromosomes. ADCAII, which always presents with retinal degeneration (SCA7), and ADCAIII often referred to as the `pure' cerebellar syndrome (SCA5), are most likely homogeneous disorders. Several SCA genes have been cloned and shown to contain CAG repeats in their coding regions. ADCA is caused by the expansion of the CAG repeats, producing an elongated polyglutamine tract in the corresponding protein. The expanded repeats are variable in size and unstable, usually increasing in size when transmitted to successive generations. This locus has been mapped to chromosome 3, and it has been determined that the diseased allele associated with Spinocerebellar ataxia-7, contains 38-130 CAG repeats (near the N-terminus), compared to 7-17 in the normal allele. The exact function of this gene is not known, however, since the encoded protein contains a nuclear localization sequence, and is found to be localized in the nucleus, it has been postulated to be a potential transcription factor. Alternative splicing, resulting in transcript variants encoding different isoforms, has been noted for this gene. (provided by RefSeq)
Show More
Applications: WB, IP (-)
Reactivity: Human
Applications: WB
Reactivity: Rat
Applications: WB
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Applications: WB, IP (-)
Reactivity: Human
Results Per Page
5 10 25 50
/ 2